满贯集团(03390)发布截至2025年6月30日止六个月的中期业绩，收入5.1亿港元，同比增加17.26%;股东 应占亏损798.4万港元，上年同期股东应占溢利2100.9万港元，同比盈转亏;每股基本亏损1港仙。 ...

格隆汇8月29日丨满贯集团(03390.HK)发布公告，2025年上半年，实现收益5.10亿港元，同比增加 17.3%；毛利为1.29亿港元，同比增加19.9%；公司拥有人应占亏损为798.4万港元，上年同期公司拥有 人应占溢利为2100.9万港元；基本每股亏损1港仙。 ...

智通财经APP讯，满贯集团(03390)发布截至2025年6月30日止六个月的中期业绩，收入5.1亿港元，同比 增加17.26%;股东应占亏损798.4万港元，上年同期股东应占溢利2100.9万港元，同比盈转亏;每股基本亏 损1港仙。 ...

Financial Performance - The group's revenue for the six months ended June 30, 2025, was HKD 510.1 million, an increase of 17.3% compared to HKD 435.0 million for the same period in 2024[6]. - Gross profit for the first half of 2025 was HKD 129.2 million, up 19.8% from HKD 107.8 million in the first half of 2024[6]. - The gross profit margin increased by 0.5 percentage points to 25.3% in the first half of 2025 from 24.8% in the first half of 2024[6]. - The group reported a net loss of HKD 7.7 million for the first half of 2025, compared to a net profit of HKD 21.1 million in the first half of 2024[6]. - EBITDA for the first half of 2025 was HKD 15.9 million, down from HKD 42.8 million in the first half of 2024[6]. - Adjusted net profit for the first half of 2025 was HKD 10.6 million, compared to HKD 31.1 million in the first half of 2024[6]. - The group reported a net loss of HKD 7.67 million for the period, compared to a profit of HKD 21.12 million in the same period of 2024[26]. - Adjusted profit before tax for the group was a loss of HKD 7.38 million, compared to a profit of HKD 24.22 million in the same period last year[26]. - The company reported a loss attributable to equity holders of HKD 8.0 million, compared to a profit of HKD 21.0 million in the same period last year[66]. - EBITDA for the first half of 2025 was a loss of HKD 7.7 million, compared to a profit of HKD 21.1 million in the first half of 2024[68]. Revenue Breakdown - Total revenue for the six months ended June 30, 2025, reached HKD 540.79 million, a 21.5% increase from HKD 444.92 million in the same period of 2024[26]. - Distribution segment revenue was HKD 354.50 million, up from HKD 343.80 million year-over-year, while e-commerce segment revenue was HKD 104.84 million, with no revenue reported for the same period in 2024[26]. - Retail store segment revenue decreased to HKD 81.45 million from HKD 101.12 million in the previous year, reflecting a decline of 19.5%[26]. - Sales in Hong Kong decreased to HKD 336,636,000 from HKD 358,406,000, a decline of 6.3%[29]. - Revenue from Hong Kong decreased by 6.1% to HKD 336.6 million, while revenue from Macau fell by 5.1% to HKD 42.9 million due to weakened consumer demand[63]. - Revenue from Southeast Asia significantly increased by 37.6% to HKD 43.2 million, driven by ongoing development and expansion of sales channels[63]. Assets and Liabilities - Total assets as of June 30, 2025, were HKD 1,236.7 million, compared to HKD 1,005.6 million as of December 31, 2024[9]. - Total liabilities increased to HKD 711.7 million as of June 30, 2025, from HKD 516.6 million as of December 31, 2024[10]. - Total equity as of June 30, 2025, was HKD 525.0 million, up from HKD 489.0 million as of December 31, 2024[10]. - Total assets as of June 30, 2025, amounted to HKD 1,236.71 million, an increase from HKD 1,005.56 million as of December 31, 2024[27]. - Total liabilities increased to HKD 711.71 million from HKD 516.61 million at the end of 2024, indicating a rise in financial obligations[27]. - The group's debt-to-equity ratio increased to 44.8% as of June 30, 2025, compared to 38.3% as of December 31, 2024, due to a higher percentage increase in net debt than total equity[71]. - Total borrowings included secured bank loans of approximately HKD 279.3 million and unsecured bank loans of approximately HKD 80.8 million as of June 30, 2025, compared to HKD 231.3 million and HKD 39.0 million respectively as of December 31, 2024[72]. Expenses and Costs - The cost of goods sold increased to HKD 379,579,000, up 16.4% from HKD 326,091,000 in the previous year[30]. - Employee benefits expenses rose significantly to HKD 43,295,000, an increase of 37.7% compared to HKD 31,456,000 in 2024[30]. - Selling and distribution expenses increased by 61.3% to HKD 71.7 million, primarily due to higher advertising and promotional costs[64]. - The total employee cost for the review period was approximately HKD 43.3 million, up from HKD 31.5 million in the previous year[85]. Dividends and Shareholder Returns - The board has resolved not to declare any interim dividend for the first half of 2025, consistent with the first half of 2024[6]. - The company did not declare any dividends for the six months ended June 30, 2025, consistent with the previous year[36]. - The company did not recommend any interim dividend for the review period, consistent with the previous year[86]. Strategic Initiatives and Market Position - The company plans to continue monitoring performance across its operating segments to make informed resource allocation decisions[22]. - The company aims to expand its presence in the Southeast Asian market, capitalizing on the region's growth potential[42]. - The company has diversified its operations across distribution, retail, and e-commerce segments, enhancing its market position in Hong Kong, Macau, mainland China, and Southeast Asia[43]. - The group continues to provide comprehensive marketing and management services for its agency brands, enhancing its product portfolio and business diversification to improve market share and gross margin[49]. - The group has registered over 60 trademarks for its own brand products, with popular items including "BG Pro Immunoglobulin Capsules" and "Kinmen Qiangxiao Essential Oil Patches"[50]. - The group is actively upgrading its own brand products to meet market demand, including enhanced versions of "BG Pro Brain Active" and "Kinmen Qiangxiao Pain Relief Gel"[50]. - The group has established procurement centers in various countries, including Japan, South Korea, and Singapore, to diversify its product offerings and enhance international presence[53]. - The Southeast Asian market has shown strong performance, with distribution sales particularly robust in Singapore and Malaysia, contributing significantly to revenue growth[53]. - The group has secured exclusive distribution rights for several brands in Malaysia, including Tianjin Tongrentang, which has popular products like "Vegetarian White Phoenix Pills" and "Compound Phlegm-Relieving Syrup" contributing to local sales[53]. - The group has formed partnerships with major personal care chains in Malaysia and Singapore, expanding its retail network and becoming a key player in the traditional Chinese medicine and health product market[55]. - The strategic acquisition of CWA is expected to enhance the company's presence in Southeast Asia and improve operational compliance across the region[60]. - The company plans to adjust its product mix and market strategies in response to the traditional tourism peak season in the second half of the year[59]. - The company aims to diversify its business and reduce risks by implementing different development strategies tailored to various regions and local cultures[58]. Share Issuance and Capital Management - The company entered into a subscription agreement with Jacobson Group Treasury Limited to issue 94 million shares at HKD 0.5 per share, raising approximately HKD 47 million[44]. - The subscription price represented a 25% premium over the closing price of HKD 0.4 on the agreement date[44]. - The net proceeds from the subscription are intended for investment in core business growth, supply chain improvements, and general working capital[44]. - The net proceeds from the subscription agreement amount to approximately HKD 46.7 million, with allocations for inventory purchases and marketing activities[56]. - As of June 30, 2025, the group has utilized HKD 20.7 million of the net proceeds, with HKD 26 million remaining for future operational needs[57]. Compliance and Governance - The audit committee reviewed the group's accounting principles and practices, ensuring that the unaudited condensed consolidated financial statements fairly presented the group's financial position and performance during the review period[92]. - The mid-term performance announcement and report for 2025 were published on the Hong Kong Stock Exchange and the company's website, containing all information required by listing rules[93].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 滿貫集團控股有限公司（「本公司」）董事會（「董事會」）謹此宣佈，本公司將於2025年8月29日（星期五） 舉行董事會會議，藉以（其中包括）考慮及通過本公司及其附屬公司截至2025年6月30日止六個月的中 期業績，及考慮派發中期股息（如有）。 代表董事會 滿貫集團控股有限公司 主席、執行董事兼行政總裁 王嘉俊 Tycoon Group Holdings Limited 滿貫集團控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：3390） 香港，2025年8月15日 董事會召開日期 於本公告日期，執行董事為王嘉俊先生；非執行董事為吳君豪先生、曹冉先生、梁艷女士、李家華 女士及劉家安先生；以及獨立非執行董事為鍾兆華先生、陳嘉麗女士及麥仲康先生。 ...

Group 1 - The core viewpoint of the article highlights significant adjustments in the overseas holdings of domestic private equity firms, particularly focusing on the changes in the portfolio of Jinglin Asset Management [1][2][3] Group 2 - Jinglin Asset's top holdings in US stocks as of the end of Q2 2025 include Meta, which accounts for 25.46% of its portfolio, with a market value exceeding $730 million [2] - The total value of Jinglin Asset's US stock holdings reached $2.873 billion, approximately 20.6 billion RMB, indicating a substantial shift towards internet companies [2] - The firm has sold off several major tech stocks, including Apple, UnitedHealth Group, Regeneron Pharmaceuticals, Pfizer, Legend Biotech, and ZTO Express [2] - The new focus on internet stocks is evident, with significant positions in companies like NetEase, Manbang Group, Pinduoduo, Futu Holdings, and 360 DigiTech [2] Group 3 - Jinglin Asset expressed optimism about China's future development, noting a shift in the competitive strength of Chinese companies from being undervalued to attracting global investment [3] - The new generation of Chinese entrepreneurs is seen as having advantages over the previous generation, leveraging a strong supply chain and engineering talent to create aesthetically pleasing products [3] - Dongfang Harbor's overseas fund has also accelerated its portfolio adjustments, reducing holdings in Nvidia, Amazon, and Apple, while increasing positions in Alphabet, Montreal Bank, and initiating purchases of Tesla, Netflix, and Coinbase [3]

Group 1 - The company, Man Kwan Group (03390), expects to report a loss of not less than HKD 7 million for the first half of 2024, compared to a profit of HKD 24.2 million for the same period in 2023 [1] - The challenges faced by the company's Chinese e-commerce division and a decrease in consumer purchasing sentiment are contributing factors to the expected loss [1] - Despite the anticipated loss, the company expects to achieve revenue growth and maintain stable gross margins in the first half of 2025 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 Tycoon Group Holdings Limited 滿貫集團控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：3390） 盈利警告 本公告乃由滿貫集團控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）根據香港聯合交易所 有限公司（「聯交所」）證券上市規則（「上市規則」）第13.09條及內幕消息條文（定義見上市規則）所作 出。 本公司董事（「董事」）會（「董事會」）謹此通知本公司股東（「股東」）及潛在投資者，根據本集團截至2025 年6月30日止六個月（「2025年上半年」）的未經審核綜合管理賬目的初步評估及目前可獲得的資料，相 比本集團截至2024年6月30日止六個月（「2024年上半年」）的除稅前溢利24.2百萬港元，預期本集團將 錄得虧損不少於7.0百萬港元。 本集團已於2025年上半年回購Combo Win Asia Limited（「CWA」，連同其附屬公司統稱為「CWA ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 公司名稱: 滿貫集團控股有限公司 (於開曼群島註冊成立的有限公司) 呈交日期: 2025年8月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03390 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 HKD | | 100,000,000 | 本月底法定/註冊股本總額： HK ...

Group 1 - The company, Man Kwan Group, has entered into a subscription agreement with Jacobson Group Treasury Limited to issue 94 million shares at a subscription price of HKD 0.5 per share, which represents 11.75% of the company's existing share capital as of the announcement date [1][2] - The total proceeds from the subscription are expected to be HKD 47 million, with a net amount of approximately HKD 46.7 million after expenses, intended for investment in core business growth, supply chain and logistics improvement, and general working capital [1][2] - The board believes that the subscription will enhance the financial position of the group and provide operational funds for future developments and obligations, with the subscriber intending to hold the equity long-term [2] Group 2 - The collaboration with Jacobson Group, a leading pharmaceutical company, is expected to create strategic synergies, leveraging both parties' expertise in healthcare and health products [2] - The subscription agreement is considered to be on normal commercial terms and is deemed fair and reasonable, aligning with the overall interests of the company and its shareholders [2] - The partnership aims to capitalize on emerging market opportunities, optimize financial leverage, and ultimately enhance long-term shareholder value [2]